Stemline Therapeutics, Inc.
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on development and commercialization of novel oncology therapeutics. ELZONRIS (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and available in the US for treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, a marketing authorization application (MAA) is under review. ELZONRIS is being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML). Additional pipeline candidates include: felezonexor (SL-801; XPO1 inhibitor; Phase 1 in advanced solid tumors ongoing), SL-1001 (novel RET kinase inhibitor, IND-enabling studies ongoing), SL-701 (immunotherapeutic; Phase 2 in glioblastoma completed), and SL-901 (novel kinase inhibitor; IND-enabling studies ongoing). For more information, please visit www.stemline.com.